Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma

This study is testing a drug called sacituzumab govitecan in people with advanced squamous cell carcinoma of the esophagus (a type of throat/food-pipe cancer) who have already tried standard treatments. Sacituzumab govitecan is an antibody-drug conjugate — it targets a protein called Trop-2 found on cancer cells and delivers chemotherapy directly to them, aiming to be more effective with fewer side effects than traditional chemo. **You may be eligible if:** - You are 18 or older with a confirmed diagnosis of squamous cell carcinoma of the esophagus - Your cancer is advanced (not removable by surgery, has come back, or spread to other parts of the body) - You have already received platinum-based chemotherapy AND an immunotherapy drug (anti-PD-1/PD-L1), and the cancer progressed - You are in reasonably good physical condition (able to carry out light work) - Your blood counts, liver, and kidney function meet the required levels **You may NOT be eligible if:** - You have not tried prior chemotherapy and immunotherapy for this cancer - Your cancer has not been confirmed as squamous cell type - Your overall physical health is significantly declining - You have severe liver or kidney problems Talk to your doctor to see if this trial is right for you.